Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist PIPE-307 to treat relapsing-remitting multiple sclerosis (RRMS).
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...
Hosted on MSN11mon
MS drug developer Contineum files for $150M IPOContineum Therapeutics (CTNM), which is developing therapies for multiple sclerosis ... 1 study for its candidate PIPE-791 for MS and IPF. Its second candidate, PIPE-307, which is being developed ...
progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical ...
progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression.
progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback